Ann: Business Activity Statement & Appendix 4C - Mar-2024 Qtr, page-2

No evidence for an impact of the RCT results on uptake by ECPs in the US, so not a lot of joy there.

A couple of things that took the eye though:

• Menicon bloom seems to out-selling Naturalvue to some extent, suggesting the Menicon release in Europe is gaining traction, influencing the gross margin. The margin for VTI on a sale of menicon bloom day will be considerably lower than a sale in the US to an ECP via a distributor.
• A strong statement on the relative efficacy of Naturalvue vs Misight based on further statistical analysis of the 1-year RCT result by the independent CRO. This needs to get into a peer-reviewed paper asap so ECPs take notice.

More evidence of strong sales now would have been welcome, but the relative performance is where the long-term return will come from IMO.